{"entity": "researcher", "timestamp": "2026-08-20T20:39:59.326Z", "family": "Juhlin", "given": "C Christofer", "initials": "CC", "orcid": "0000-0002-5945-9081", "affiliations": ["Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.", "Department of Pathology and Cytology, Karolinska University Hospital Solna, Stockholm, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/c155b3a3146b41909170a016a7f5b07a.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/c155b3a3146b41909170a016a7f5b07a"}}, "publications": [{"entity": "publication", "iuid": "ccdc037f99d04f6c8e00541d24b23cf5", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/ccdc037f99d04f6c8e00541d24b23cf5.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/ccdc037f99d04f6c8e00541d24b23cf5"}}, "title": "CD44v6 expression in non-anaplastic thyroid carcinoma: characterization of candidates for targeted therapy.", "authors": [{"family": "Stenman", "given": "Adam", "initials": "A"}, {"family": "Nilsson", "given": "Joachim N", "initials": "JN"}, {"family": "Condello", "given": "Vincenzo", "initials": "V"}, {"family": "L Mortensen", "given": "Anja C", "initials": "AC"}, {"family": "Nestor", "given": "Marika", "initials": "M"}, {"family": "Zedenius", "given": "Jan", "initials": "J"}, {"family": "Juhlin", "given": "C Christofer", "initials": "CC", "orcid": "0000-0002-5945-9081", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c155b3a3146b41909170a016a7f5b07a.json"}}], "type": "journal article", "published": "2025-10-03", "journal": {"title": "Thyroid Res", "issn": "1756-6614", "volume": "18", "issue": "1", "pages": "47", "issn-l": null}, "abstract": "CD44v6 is a membranous antigen upregulated in solid tumors and a promising molecular radiotherapy target, especially in anaplastic thyroid carcinoma (ATC). A Phase 1 trial recently launched to evaluate the lutetium-labeled anti-CD44v6 antibody [1\u2077\u2077Lu]Lu-DOTA-AKIR001 in CD44v6-positive solid tumors. Given limited data in non-ATC, we assessed CD44v6 immunoreactivity in tumors that may progress to a radioiodine-refractory state.\n\nAn exploratory cohort of 33 tumors (30 papillary thyroid carcinomas [PTCs], 3 poorly differentiated thyroid carcinomas [PDTCs]) was screened using the VFF-7 antibody, supported by detailed iodine concentration, genetic, and RNA sequencing data. A validation cohort of 40 oncocytic thyroid carcinomas (OTCs), 28 additional PDTCs, and one differentiated high-grade thyroid carcinoma was also screened using two antibody clones, VFF-7 and VFF-18.\n\nIn the exploratory cohort, 10 of 33 tumors (30%) showed focal or diffuse CD44v6 expression, while the rest were negative. Among OTCs in the validation cohort, 15 of 40 (38%) were partially or diffusely positive, and in PDTCs, 14 of 28 (50%) showed focal or diffuse staining. The VFF-7 and VFF-18 clones produced similar patterns.\n\nSubstantial subsets of non-ATCs express CD44v6, indicating that some patients may be candidates for [1\u2077\u2077Lu]Lu-DOTA-AKIR001 radiotherapy, particularly when conventional treatments are exhausted.", "doi": "10.1186/s13044-025-00266-3", "pmid": "41039489", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12492884"}, {"db": "pii", "key": "10.1186/s13044-025-00266-3"}], "notes": [], "created": "2026-08-20T12:21:23.208Z", "modified": "2026-08-20T12:21:23.293Z"}, {"entity": "publication", "iuid": "e1a9e93abdc94a7aac7484a984c1d973", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/e1a9e93abdc94a7aac7484a984c1d973.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/e1a9e93abdc94a7aac7484a984c1d973"}}, "title": "Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts.", "authors": [{"family": "Lundgren Mortensen", "given": "Anja Charlotte", "initials": "AC", "orcid": "0000-0002-6771-3289", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/85c16524674b49e5a8d24fdae955e8f2.json"}}, {"family": "Berglund", "given": "Hanna", "initials": "H", "orcid": "0009-0007-1754-1822", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/e89dca9798db436499e12cf23291e1d3.json"}}, {"family": "Jha", "given": "Preeti", "initials": "P", "orcid": "0000-0001-9943-5976", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4229e04c150b47458431de671cc0e05b.json"}}, {"family": "Stenman", "given": "Adam", "initials": "A", "orcid": "0000-0003-3248-7629", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8fd6c3e9b7644d7c90708d1250ea008b.json"}}, {"family": "Selvaraju", "given": "Ram Kumar", "initials": "RK", "orcid": "0000-0001-9219-1497", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/83711532c31f4f1dad8bd6c3495b9c08.json"}}, {"family": "Lundqvist", "given": "Hans", "initials": "H", "orcid": "0009-0002-4859-1332", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/7f729923c1c74e3a8015e1b76500e97f.json"}}, {"family": "Hofstr\u00f6m", "given": "Camilla", "initials": "C", "orcid": "0009-0008-6407-9893", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/30fb64ebeda84e4bbf280166f56ec46f.json"}}, {"family": "Persson", "given": "Helena", "initials": "H", "orcid": "0009-0004-6053-0801", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/aba54ede629f4464b916d9d734859cc0.json"}}, {"family": "Juhlin", "given": "C Christofer", "initials": "CC", "orcid": "0000-0002-5945-9081", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c155b3a3146b41909170a016a7f5b07a.json"}}, {"family": "Zedenius", "given": "Jan", "initials": "J", "orcid": "0000-0003-2833-3758", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/d3ff2a15cd7d4d8aa46b15c0e2d0f261.json"}}, {"family": "Frejd", "given": "Fredrik Y", "initials": "FY", "orcid": "0000-0002-6421-4142", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/0bf87385618f44ddae90e48177849e4e.json"}}, {"family": "Nestor", "given": "Marika", "initials": "M", "orcid": "0000-0003-4662-3142", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/11ccea08af3f404bbdf67a68ee8f1de4.json"}}], "type": "journal article", "published": "2025-05-02", "journal": {"title": "Mol. Cancer Ther.", "issn": "1538-8514", "volume": "24", "issue": "5", "pages": "753-762", "issn-l": "1535-7163"}, "abstract": "Anaplastic thyroid cancer (ATC) is a rare but severe form of thyroid cancer responsible for approximately 50% of thyroid cancer deaths. Consequently, the identification of innovative therapies remains crucial for the effective treatment of ATC. Molecular radiotherapy is a rapidly growing field within oncology, and the cell surface antigen CD44v6, which is overexpressed in several cancers, is a plausible target for molecular radiotherapy of ATC. IHC of 39 patient samples with ATC was evaluated for CD44v6 expression. Biodistribution and dosimetry of iodine-125 (125I)-/lutetium-177 (177Lu)-labeled UU-40, a CD44v6-specific antibody, followed by in vivo efficacy in two ATC xenograft models with varying target expression levels (ACT-1 and BHT-101), accompanied by single-photon emission computed tomography (SPECT) imaging, evaluated radiolabeled UU-40 for therapeutic efficiency in ATC xenografts. The IHC revealed CD44v6 immunoreactivity in 46% of patient samples with ATC. The biodistribution favored 177Lu-labeled UU-40 over the 125I-labeled antibody and confirmed the in vivo specificity of both radioconjugates. The in vivo efficacy and accompanied SPECT imaging of a moderate CD44v6-expressing xenograft model (BHT-101) verified the tumor specificity, as well as the target-specific effect of 177Lu-labeled UU-40 on tumor growth and survival. A 100% complete response rate was demonstrated as a result of therapy using a single dose of 16 MBq 177Lu-labeled UU-40 in a high CD44v6-expressing xenograft model (ACT-1), and SPECT imaging revealed excellent tumor uptake of the radioconjugate at 14 days after injection. This study verifies the expression of CD44v6 in ATC and strengthens the superiority and promise of 177Lu-labeled UU-40 over 131I-labeled UU-40 for antibody-based molecular radiotherapy of CD44v6-positive ATC.", "doi": "10.1158/1535-7163.MCT-24-0524", "pmid": "39976160", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12046332"}, {"db": "pii", "key": "752016"}], "notes": [], "created": "2026-08-20T12:12:49.341Z", "modified": "2026-08-20T12:12:49.856Z"}, {"entity": "publication", "iuid": "0982a4fafbd9457fa5129dfa54859ac3", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/0982a4fafbd9457fa5129dfa54859ac3.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/0982a4fafbd9457fa5129dfa54859ac3"}}, "title": "Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors.", "authors": [{"family": "Fotouhi", "given": "Omid", "initials": "O"}, {"family": "Kjellin", "given": "Hanna", "initials": "H"}, {"family": "Juhlin", "given": "C Christofer", "initials": "CC", "orcid": "0000-0002-5945-9081", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c155b3a3146b41909170a016a7f5b07a.json"}}, {"family": "Pan", "given": "Yanbo", "initials": "Y"}, {"family": "Vesterlund", "given": "Mattias", "initials": "M", "orcid": "0000-0001-9471-6592", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/e443cdb01cc44a7fa786941b5c0b62d6.json"}}, {"family": "Ghaderi", "given": "Mehran", "initials": "M"}, {"family": "Yousef", "given": "Abdelhamid", "initials": "A"}, {"family": "Andersson-Sand", "given": "Hillevi", "initials": "H"}, {"family": "Kharaziha", "given": "Pedram", "initials": "P"}, {"family": "Caramuta", "given": "Stefano", "initials": "S"}, {"family": "Kjellman", "given": "Magnus", "initials": "M"}, {"family": "Zedenius", "given": "Jan", "initials": "J"}, {"family": "Larsson", "given": "Catharina", "initials": "C"}, {"family": "Orre", "given": "Lukas M", "initials": "LM"}], "type": "journal article", "published": "2019-10-00", "journal": {"title": "Oncogene", "issn": "1476-5594", "volume": "38", "issue": "43", "pages": "6881-6897", "issn-l": "0950-9232"}, "abstract": "Patients with small intestinal neuroendocrine tumors (SI-NETs) frequently develop spread disease; however, the underlying molecular mechanisms of disease progression are not known and effective preventive treatment strategies are lacking. Here, protein expression profiling was performed by HiRIEF-LC-MS in 14 primary SI-NETs from patients with and without liver metastases detected at the time of surgery and initial treatment. Among differentially expressed proteins, overexpression of the ubiquitin-like protein NEDD8 was identified in samples from patients with liver metastasis. Further, NEDD8 correlation analysis indicated co-expression with RBX1, a key component in cullin-RING ubiquitin ligases (CRLs). In vitro inhibition of neddylation with the therapeutic agent pevonedistat (MLN4924) resulted in a dramatic decrease of proliferation in SI-NET cell lines. Subsequent mass spectrometry-based proteomics analysis of pevonedistat effects and effects of the proteasome inhibitor bortezomib revealed stabilization of multiple targets of CRLs including p27, an established tumor suppressor in SI-NET. Silencing of NEDD8 and RBX1 using siRNA resulted in a stabilization of p27, suggesting that the cellular levels of NEDD8 and RBX1 affect CRL activity. Inhibition of CRL activity, by either NEDD8/RBX1 silencing or pevonedistat treatment of cells resulted in induction of apoptosis that could be partially rescued by siRNA-based silencing of p27. Differential expression of both p27 and NEDD8 was confirmed in a second cohort of SI-NET using immunohistochemistry. Collectively, these findings suggest a role for CRLs and the ubiquitin proteasome system in suppression of p27 in SI-NET, and inhibition of neddylation as a putative therapeutic strategy in SI-NET.", "doi": "10.1038/s41388-019-0938-8", "pmid": "31406256", "labels": [], "xrefs": [{"db": "pii", "key": "10.1038/s41388-019-0938-8"}], "notes": [], "created": "2026-08-20T08:48:19.511Z", "modified": "2026-08-20T08:48:19.644Z"}]}